title: Investigation of molecular serum profiles associated with predisposition to antipsychotic-induced weight gain.
abstract: OBJECTIVE
  Metabolic disturbances are major adverse side effects in the treatment of schizophrenia patients with antipsychotics. A substantial proportion of patients discontinue treatment with second-generation antipsychotics due to weight gain. The objective of this study was to investigate molecular factors predisposing patients to the development of such metabolic disturbances.
  
  
  METHODS
  We investigated whether serum molecules measured before treatment initiation were associated with subsequent weight gain following a 6-week treatment with antipsychotics. The concentrations of 191 molecules were measured longitudinally in serum from 77 schizophrenia patients using multiplex immunoassays.
  
  
  RESULTS
  This showed that the levels of 10 serum molecules at T0 were significantly associated with ΔBMI, which included interleukin-6 receptor, epidermal growth factor and thyroid stimulating hormone.
  
  
  CONCLUSIONS
  Our results suggest that patients who experience antipsychotic-induced weight gain have specific molecular alterations already prior to treatment. Further studies are required to validate and evaluate current findings in the context of response and side-effect development. This may ultimately lead to molecular tests that can aid in the selection of antipsychotic treatments.
authors.affiliation: Department of Chemical Engineering and Biotechnology, University of Cambridge , Cambridge , UK.
authors.forename: Emanuel
authors.initials: E
authors.lastname: Schwarz
authors.forename: Johann
authors.initials: J
authors.lastname: Steiner
authors.forename: Paul C
authors.initials: PC
authors.lastname: Guest
authors.forename: Bernhard
authors.initials: B
authors.lastname: Bogerts
authors.forename: Sabine
authors.initials: S
authors.lastname: Bahn
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015992:Body Mass Index; D003024:Clozapine / Q000009:adverse effects* / Q000627:therapeutic use; D004198:Disease Susceptibility; D066246:ErbB Receptors / Q000097:blood; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D019947:Receptors, Interleukin-6 / Q000097:blood; D011989:Receptors, Thyrotropin / Q000097:blood; D018967:Risperidone / Q000009:adverse effects* / Q000627:therapeutic use; D012559:Schizophrenia / Q000097:blood* / Q000188:drug therapy*; D015430:Weight Gain / Q000187:drug effects*; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; C508603:IL6R protein, human; D019947:Receptors, Interleukin-6; D011989:Receptors, Thyrotropin; C512478:EGFR protein, human; D066246:ErbB Receptors; D003024:Clozapine; D018967:Risperidone
keywords: Schizophrenia; antipsychotics; biomarkers; proteomics; side effects